enGene
Vancouver
About enGene
enGene is a developer of a mucosal immunotherapy platform designed to treat inflammatory bowel disease and diabetes. The company's mucosal immunotherapy platform has developed a flexible nucleotide delivery technology targeting mucosal tissues to treat numerous prevalent, chronic diseases via the induction or suppression of protein expression levels, enabling physicians and doctors to regenerate physiologic, meal-regulated insulin secretion from the gut of subjects with diabetes.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $10K – $50K
- Total funding: $409.6M
- Funding stage: IPO
- Last round: Post-IPO Debt (Jan 2026)
- Ticker: nasdaq:ENGN
- Website: engene.com
- Phone: 604-221-4362
Industries & Categories
Biotechnology, Diabetes, Genetics, Health Care
Social Profiles
Canonical: https://fsome.com/organization/engene-27744 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.